Skip to content
BioRegenis — home

Advancing regenerative biotechnology

We develop therapies that help tissue rebuild itself

Two programmes in development, tracked phase by phase. Progress is public and kept current.

See the pipelineInvest in BioRegenis

Average progress 74.5%

About us

BioRegenis is an Italian biotech startup. We develop pharmaceutical and health products, from research through to industrial development.

Where we stand

Every programme moves through the standard phases of pharmaceutical development. Here is exactly where each one sits, updated by our team.

BioChip Skin

49%

  1. Preclinical
  2. Phase I
  3. Phase II
  4. Phase III
  5. Phase IV

Caregamers

Product line for gamer wellbeing and performance

100%

  1. Preclinical
  2. Phase I
  3. Phase II
  4. Phase III
  5. Phase IV

The five phases indicate each programme's internal development status, from initial research through to market.

Full details

How we work

  • Verifiable phases

    From preclinical through Phase IV, every step follows defined protocols and leaves a documentary trail.

  • Public progress

    We don't wait for the press release. The status of every programme can be checked at any time.

  • Applied research

    We work on concrete clinical problems, with measurable targets and stated timeframes.

Interested in investing?

We collect expressions of interest. No payment takes place on this site.

Investors section